Plasma kallikrein binding proteins

A method of treating a plasma kallikrein associated disorder in a subject, the method comprising:

• administering an antibody that binds to the active form of human plasma kallikrein to a subject in need thereof, wherein the antibody comprises:
• (i) a heavy chain variable region comprising a complementary determining region (CDR) 1 set forth as HYIMM (SR) ID NO:
• 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO:
• 167), and a CDR3 set forth as RRIGVPRRDEFDI (SEQ ID NO:
• 1171);
• and
• (ii) a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO:
• 1172), a CDR2 set forth as KASTLES (SEQ ID NO:
• 1173), and a CDR3 set forth as QQYNTYWT (SEQ ID NO:
• 1174).

A method of detecting plasma kallikrein in a subject, the method comprising:

• contacting an antibody that binds to the active form of human plasma kallikrein with a biological sample of a subject in need thereof;
• and detecting an interaction between the antibody and the plasma kallikrein in the biological sample, if present, wherein the antibody comprises:
• (i) a heavy chain variable region comprising a complementary determining region (CDR) 1 set forth as HYIMM (SEQ ID NO:
• 166), a CDR2 set forth as GIYSSGGITVYADSVKG (SEQ ID NO:
• 167), and a CDR3 set forth as RRIGVPRRDEFDI (SEQ ID NO:
• 1171);
• and
• (ii) a light chain variable region comprising a CDR1 set forth as RASQSISSWLA (SEQ ID NO:
• 1172), a CDR2 set forth as KASTLES (SEQ ID NO:
• 1173) and a CDR3 set forth as QQYNTYWT (SEQ ID NO:
• 1174).